We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Daniel Mark

Daniel B Mark MD, MPH

Professor of Medicine, Vice Chief for Academic Affairs, Division of Cardiology, Department of Medicine, Duke University Medical Center, Director, Outcomes Research, Duke Clinical Research Institute, Editor-in-Chief, American Heart Journal

Dr. Daniel B. Mark is a Professor of Medicine in the Division of Cardiology, a highly respected clinician, researcher, educator and an internationally recognized academic leader.  

He has served for 30 years as an attending physician in the Duke Cardiac Care Unit and was also, for a time, Direction of Inpatient Cardiology Consults.  He continues to round in the CCU regularly and serves as the Vice Chair for Academic Affairs in the Division of Cardioogy. He is also a senior faculty member in the Duke Clinical Research Institute (DCRI) and, in that organization, directs the largest academic Outcomes Research group in the world.  For the last 11 years, he has been the PI of an NHLBI T32 grant that has trained many of the current younger faculty in the Division of Cardiology. The most recent renewal of this grant received a perfect score from the review panel.

Dr. Mark has produced over 305 peer-reviewed original papers. He has also edited 2 books and has written 80 book chapters as well as numerous editorials. Dr. Mark has numerous principal author publications in the top clinical research journals including the New England Journal of Medicine, Annals of Internal Medicine, JAMA, and Circulation.  In 1997, he received the first Research Excellence Award given by the Association for Pharmacoeconomics and Outcomes Research, the leading academic professional organization in the outcomes field. Dr. Mark has also been honored by election into the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP).  In 2009, Dr. Mark received the American College of Cardiology’s Distinguished Scientist Award for his work in outcomes research. Dr. Mark has been the principal investigator on major R01 grants from the NHLBI and the Agency for Health Research and Quality (AHRQ) with funding to do outcomes research from these organizations continuously since 1987.  He is currently PI on five R01 grants from NHLBI that are measuring patient reported outcomes and assessing cost effectiveness in major cardiovascular clinical trials. Each one of these trials is likely to have a major impact on clinical practice and health policy within the next decade. Dr. Mark’s work has formed the basis for recommendations in national clinical practice guidelines in the U.S. and abroad.  His work is also featured prominently in some of the most prestigious medical textbooks.  He has served and continues to serve on numerous national policy committees focused on improving quality and outcomes of cardiovascular care.

In 2015, he was appointed as Editor-in-Chief of the American Heart Journal, the oldest peer-review journal in cardiovascular medicine. He served as the journal’s Editor from 1996-2015.

Dr. Mark received his medical degree from Tufts in Boston and an MPH from Harvard.  He completed a residency in Internal Medicine at the University of Virginia before coming to Duke in 1982 for a cardiology fellowship. He joined the Duke faculty in 1985.    

Disclosures

Dr. Mark has received grant funding from Eli Lilly & Company, Medtronic, Gilead, AstraZeneca, AGA Medical, and Bristol Myers Squibb and he has received consulting fees from Milestone Pharmaceuticals, Medtronic, CardioDx, and St Jude Medical.

 

Recent Contributions to PracticeUpdate:

  1. Cost-Effectiveness of Imaging Strategy for Stable Chest Pain